Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance
详细信息 查看全文
- 作者：Jeong Eun Leea ; 1 ; Hee Sun Parka ; 1 ; Dahye Leea ; Geon Yoob ; Tackhoon Kimc ; Haeyon Jeonc ; Min-Kyung Yeod ; Choong-Sik Leed ; Jae Young Moona ; Sung Soo Junga ; Ju Ock Kima ; Sun Young Kima ; Dong Il Parka ; Yeon Hee Parka ; Jae Cheol Leee ; In-Jae Ohf ; Dae Sik Limb ; Chaeuk Chunga ; universe7903@gmail.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：YAP ; EGFR ; KRAS ; Resistance ; Lung cancer
- 刊名：Biochemical and Biophysical Research Communications
- 出版年：2016
- 出版时间：20 May 2016
- 年：2016
- 卷：474
- 期：1
- 页码：154-160
- 全文大小：2060 K
文摘
- class="listitem" id="list_ulist0010">
- class="label">•
YAP plays a crucial role in the EGFR-TKI resistance of lung adenocarcinoma.
- class="label">•
YAP increases the expression of AXL that induces the resistance to EGFR-TKI in lung adenocarcinoma.
- class="label">•
Increased YAP expression in gefitinib resistant cells is independent of the canonical Hippo pathway.
- class="label">•
Combination of YAP inhibitor and EGFR-TKI can be helpful for overcoming the EGFR-TKI resistance.